Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future Post published:November 30, 2024 Post category:Analysis/News/Pα+
Q3’24 Survey: What are Psychedelics Investors Concerned About? Post published:November 27, 2024 Post category:Analysis/News/Pα+
Interviews: Meet the Team Who Challenged the DEA on DOI and DOC Post published:November 26, 2024 Post category:Analysis/News
Q3’24 Survey: What are Psychedelics Investors Excited About? Post published:November 25, 2024 Post category:Analysis/News/Pα+
Dispatch From the DEA: DOI and DOC on Trial As Scientists Challenge Psychedelic Scheduling Bid Post published:November 18, 2024 Post category:Analysis/News
Tripping Over Trump: Will the New Administration Embrace Psychedelic Exceptionalism or ‘Just Say No’? Post published:November 14, 2024 Post category:Analysis/News
Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and Decriminalisation Post published:November 6, 2024 Post category:Analysis/News
Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates Post published:November 4, 2024 Post category:Analysis/News